Today that agreement was officially signed at the WFH 2022 World Congress in Montreal, Canada. The donation includes product specifically manufactured to have a longer shelf life, allowing more people around the world to access life-saving therapy. The new agreement comes as CSL Behring enters its 5th multiyear commitment to donate factor to the WFH Humanitarian Aid Program.
From the WFH, Cesar Garrido, President; Eric Stolte, WFH USA President, Alain Baumann, CEO; and Assad E. Haffar, MD, Medical & Humanitarian Aid Director; were present to officially sign the agreement. From the CSL Behring team, Antti Kourula, Krupa Sivarmurthy, Courtney Wilson and Leah Williams were present. To read more about the original announcement, please click here.
About the WFH Humanitarian Aid Program
The WFH Humanitarian Aid Program improves the lack of access to care and treatment by providing much-needed support for people with inherited bleeding disorders in developing countries. By providing patients with a more predictable and sustainable flow of humanitarian aid donations, the WFH Humanitarian Aid Program makes it possible for patients to receive consistent and reliable access to treatment and care. None of this would be possible without the generous support of Sanofi and Sobi, our Founding Visionary Contributors; Bayer, CSL Behring and Roche, our Visionary Contributors; Grifols, our Leadership Contributor; and Takeda, our Contributor. To learn more about the WFH Humanitarian Aid Program, visit www.treatmentforall.org